• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Gemin X Announces Data Presentations for Its Novel, Targeted Cancer Therapies Obatoclax and GMX1777 at the 20th Annual EORTC-NCI-AACR Symposium

Posted on: Thursday, 16 October 2008, 09:00 CDT

Gemin X Pharmaceuticals announced today that clinical and preclinical data from studies of two of the Company's novel, targeted cancer therapeutics - obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor; and GMX1777, a novel inhibitor of NAD+ metabolism - will be presented during the 20th EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer Therapeutics," being held in Geneva, Switzerland from October 21 through October 24, 2008.

Details on the abstracts being presented at ENA include: Abstract Title: A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT) Poster: Pishvaian, M. (US) Poster Session: Phase 1 Poster Number: 418 Poster Date/Time: Thursday, October 23, 2008 / 12:00 pm - 5:00 pm GMT Abstract Title: Target identification permits rational development of the prodrug GMX1777 for the treatment of melanoma Poster: Watson, M.H. (CA) Poster Session: Antimetabolites Poster Number: 470 Poster Date/Time: Friday, October 24, 2008 / 12:00 pm - 4:00 pm GMT Abstract Title: Obatoclax (GX15-070), a small molecule pan-bcl-2 inhibitor, in combination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC) Poster: Chiappori, A. (US) Poster Session: Signal transduction modulators Poster Number: 592 Poster Date/Time: Friday, October 24, 2008 / 12:00 pm - 4:00 pm GMT

This ENA Symposium is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). It is organized to bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. This conference highlights many recent advances in the early development of promising new compounds at various levels of preclinical and clinical development.

About Gemin X Pharmaceuticals

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X is developing first-in-class cancer therapeutics based on reinitiating the natural process of programmed cell death, or apoptosis, and the inhibition of metabolism in cancerous cells. Gemin X currently has three clinical development programs underway, ranging from Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, to preclinical studies for its Telomere Capping program. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including elderly acute myeloid leukemia (AML), mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis. Founded in 1998, Gemin X is privately held with drug development and executive headquarters in Malvern, Pennsylvania and drug discovery operations in Montreal, Canada.

Source: Business Wire

More News in this Category